<DOC>
	<DOCNO>NCT02373995</DOCNO>
	<brief_summary>Graves ' orbitopathy ( GO ) , also know thyroid eye disease , affect approximately 3 million people Europe estimate socioeconomic burden 6.4 billion euro per annum . GO complication Graves ' disease autoimmune disease commonest cause overactive thyroid gland . The treatment GO remain unsatisfactory majority patient report long-term impairment quality life . The effect gut derive antigen , micro-organisms nutrient , autoimmune response test animal model probiotic `` contra-biotic '' intervention . In Indigo interventional trial investigator add standard anti-thyroid drug treatment ( ATD ) specifically design probiotic ( LAB4 , Cultech Ltd. , West Glamorgan , UK ) ass whether possible modify microbiome GD patient improve immunological status .</brief_summary>
	<brief_title>Role Microbiome Graves ' Orbitopathy</brief_title>
	<detailed_description>Investigation Novel biomakers Definition role microbiome In Graves ' Orbitopathy ( GO ) ( INDIGO ) Background Graves ' orbitopathy ( GO ) , also know thyroid eye disease , affect approximately 3 million people Europe estimate socioeconomic burden 6.4 billion euro per annum . GO complication Graves ' disease autoimmune disease commonest cause overactive thyroid gland . The treatment GO remain unsatisfactory majority patient report long-term impairment quality life . To improve outcomes people GO thus reduce long-term illness cost society , research need address identification risk factor , develop good understand pathophysiology disease , devise approach early diagnosis pre-clinical stage disease , create novel safe intervention . The effect gut derive antigen , micro-organisms nutrient , autoimmune response test animal model probiotic `` contra-biotic '' intervention . In Indigo interventional trial investigator add standard anti-thyroid drug treatment ( ATD ) specifically design probiotic ( LAB4 , Cultech Ltd. , West Glamorgan , UK ) ass whether possible modify microbiome GD patient improve immunological status . Primary objective : To modify microbiome GD patient reduce pathogenic specie enrich commensal , symbiotic component . Secondary objective : To decrease anti-TSHr antibody titer concentration IgG IgA GD patient . Experimental design The investigator interested induce potential modification gut microbioma obtain reduction anti-THSr antibody titer total IgG IgA concentration , prevent relapse development progression eye disease . In particular , expect , beneficial modification gut microbioma relate reduction end treatment least 5 % Firmicutes : Bacteroides ratio 30 % anti-TSHr antibody titer total IgG IgA concentration . Patients diagnosis Graves ' disease without OB randomize receive either ATD plus LAB4 ATD plus placebo 6 month . LAB4 consist 4 strain : Lactobacillus acidophilus CUL21 ( NCIMB 30156 ) Lactobacillus acidophilus CUL60 ( NCIMB 30157 ) Bifidobacterium bifidum CUL20 ( NCIMB 30153 ) Bifidobacterium animalis subsp . lactis CUL34 ( NCIMB 30172 ) administer orally , twice day meal , 6 month . Samples blood ( serum DNA ) , tear ( Schirmer strip ) , nasal swab faeces collect first visit , treatment within 4 week anti-thyroid drug ( ATD ) therapy commence community physician . The sample collect first occasion euthyroidism restore usual block/replace titration regimen use locally . The sample also collect 6 month cessation treatment point relapse sooner . High through-put analysis microRNA ( miRNA ) serum proteomic analysis tear serum use search biomarkers predictive eye disease progression . In addition , antibody response analyze identify microbial food derive antigen involve trigger disease associate GO progression . Moreover , 16S RNA gene sequence serve characterize patient microbiomes assess whether information use develop diagnostics individual risk GD develop GO .</detailed_description>
	<mesh_term>Graves Disease</mesh_term>
	<criteria>Group A : Untreated Graves ' hyperthyroidism ( within 4 week initiate ATD treatment ) definition hyperthyroidism : TSH decrease , FT4 /or FT3 increase definition Graves ' : diffusely enlarge thyroid gland either palpation echograpy , and/or homogeneous thyroid uptake scintigraphy , positive TSHRAb first episode recurrence Graves ' hyperthyroidism minimal eye sign , define lid retraction / lid lag sign . Planned treatment antithyroid drug either titration regimen blockandreplace regimen 18 month . Group B. Untreated Graves ' hyperthyroidism ( within 4 week initiate ATD treatment ) overt sign GO define EUGOGO1 1 . Mild GO : patient whose feature GO minor impact daily life insufficient justify immunosuppressive surgical treatment . They usually one following : minor lid retraction ( &lt; 2 mm ) , mild soft tissue involvement , exophthalmos &lt; 3 mm normal race gender , transient diplopia , corneal exposure responsive lubricant ) 2 . Moderatetosevere GO : Patients without sightthreatening GO whose eye disease sufficient impact daily life justify risk immunosuppression ( active ) surgical intervention ( inactive ) . Patients moderatetosevere GO usually one following : lid retraction R2 mm , moderate severe soft tissue involvement , exophthalmos &gt; 3 mm normal race gender , inconstant , constant diplopia . 3 . Sight threaten GO : Patients dysthyroid optic neuropathy ( DON ) and/or corneal Previous plan treatment 131I thyroidectomy ( A &amp; B ) ; sight threaten GO require decompression ( B ) ; drug interfere natural course GO ( A &amp; B ) : steroid , immunosuppressant , thiazolidinediones , antibiotic / antifungal / antiviral ( topical systemic least 4 week prior recruitment study ) ; acute diarrhea illness ( gastroenteritis least 4 week prior recruitment study ) ; Drugs interfere thyroid function ( A &amp; B ) : amiodarone , lithium , iodine supplement ; Drug alcohol abuse ( A &amp; B ) ; inform consent ( A &amp; B ) ; Age le 18 ( A &amp; B ) ; Pregnancy ( A &amp; B ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Graves</keyword>
	<keyword>Orbithopaty</keyword>
	<keyword>euthyroidism</keyword>
	<keyword>microbiome</keyword>
</DOC>